治疗2型糖尿病的新型长效胰高血糖素样肽-1受体激动剂——ecnoglutide
A novel long-acting glucagon-like peptide-1 receptor agonist for the treatment of diabetes mellitus type 2:ecnoglutide
王越 1冯东梅 1刘洋 1刘丹1
作者信息
- 1. 沈阳药科大学 制药工程学院 基于靶点的药物设计与研究教育部重点实验室,沈阳 110016
- 折叠
摘要
胰高血糖素样肽-1(GLP-1)是具有刺激胰岛素分泌和降低血糖作用的一种激素,ecnoglutide(研究代号:XW003)是一种新型的长效GLP-1受体激动剂.目前,其Ⅰ、Ⅱ期临床试验均已完成,结果表明,ecnoglu-tide治疗2型糖尿病和肥胖症具有良好的安全性和有效性,并且Ⅲ期临床试验已完成首位受试者的给药.本文主要对该药物的基本信息、作用机制、临床前研究及临床研究等方面进行概述.
Abstract
Glucagon-like peptide-1(GLP-1)is a class of hormone that plays a role in stimulating insulin secretion and lowering blood glucose.Ecnoglutide(research code:XW003)is a novel long-acting GLP-1 receptor agonist.The phase Ⅰand Ⅱ clinical trials have been completed,showing that ecnoglutide has a good safety and efficacy profile in treating type Ⅱdiabetes and obesity.Furthermore,the administration of the first subject has been completed in phase Ⅲ for the treatment of diabetes mellitus type 2.This article provides an overview of the ecnoglutide's basic information,mechanism of action,pre-clinical research,and clinical trials.
关键词
ecnoglutide/2型糖尿病/长效胰高血糖素样肽-1受体激动剂Key words
ecnoglutide/diabetes mellitus type 2/long-acting glucagon-like peptide-1 agonist引用本文复制引用
出版年
2024
NETL
NSTL
万方数据